Cell 2025

Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.

Events

In-Person & Online Events

Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.

Biologics US 2025

Oct 02 - 03, 2025 | San Diego, CA

Cell 2025

11 - 12 Nov 2025 | London, UK

Cell Leaders Awards

11 Nov 2025 | London, UK

NextGen Biomed 2026

24 - 25 Mar 2026 | London, UK

Online Activities

Our Monthly Science Exchanges and Webinars keep you connected to the conversation.

All Online Activities
Community

About

NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.

More Info

Community

NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.

More Info

Media Partners

We work with leading journal publications on reciprocal marketing arrangements.

More Info
Services

In-Person Services

At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.

More Info

Digital Marketing Services

Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.

More Info
Resources

Browse All Resources

The latest in from nextgen biomed research & development

All NextGen Biomed Resources

Latest Resources

University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus

08/11/24 - The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK.

07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants

31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine

Featured Resource

Innovative Contamination Control in Cell Therapy: Enabling Integrity and Efficiency

On-demand webinar presented by Senior Field Application Scientists, Suzy Brown and George Prout
Contact
Our Brands

Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.

Oxford Global

Precision Medicine

Discovery & Development

NextGen Biomed

15:05

Panel Discussion: NextGen Vaccine Strategies To Advance Cancer Treatment
Moderator: ANTONIO POSTIGO, Chief Scientific Officer, Stratosvir Ltd

Panel Discussion: The Next Chapter Of Oligonucleotide Delivery
Moderator: STEVE HOOD, Senior Director, Oligonucleotide ADME Strategy, DMPK, GSK

Empowering Antibody Engineering – Highlights From Early Beginnings Of Using AI-Based Tools For Optimization & Functional Engineering Of Antibody Candidates
BERIT OLSEN KROGH, Senior Research Fellow, Lundbeck

Panel Discussion: Mixed Modalities: Addressing The Challenges & Opportunities To Drug The Undruggable

Multivalent Ligand Design To Selectively Bind Proteins
NATHAN ALVES, Research Director, Indiana University School Of Medicine

15:30

Cyclotides As Ultra-Stable Combinatorial Display Platforms For Peptide-Based Drug Discovery
DAVID CRAIK, Professor, University Of Queensland

Enhancing Biologics Lead Optimisation By Combining Affinity Prediction Methods & Active Learning
OWEN VICKERY, Associate Principal Scientist, AstraZeneca

InSiDe Out: In Silico Developability Screening At AstraZeneca, Impact To Date & Future Direction
ISABELLE SERMADIRAS, Associate Principal Scientist, AstraZeneca

15:55

Unveiling Hidden Targets: AI-Driven Discovery Of Therapeutic Cancer Antigens From The Dark Genome
CHRISTIAN GARDE, Director, Evaxion

The Identification Of Cyclic Peptide Metabolic Soft Spots By Isotope-Labelled Reductive Dimethylation & Leveraging High-Resolution Ion Mobility-Mass Spectrometry
MARIA FAWAZ, Associate Principal Scientist, MS

Using The Very Small To Tackle The Very Large – Our Journey From Concept To Clinic
IJEOMA UCHEGBU, Professor Of Pharmaceutical Nanoscience, University College London

First-In-Class Site-Directed Targeted soloMER Drug Conjugate For Autoimmune Inflammation
OBINNA UBAH, Principal Scientist, Elasmogen

Rationalising MABs Developability Testing
DAVID BROCKWELL, Professor, University Of Leeds

16:20

Development & Qualification Of A Cell-Based Potency Assay For Two Novel DNA Cancer Vaccine
ELISA MARELLI, Research Scientist, Scancell

Short Novel Peptides As Chelating Agents For Metal-Related Diseases
MICHAL SHOSHAN, Founder & Chief Executive Officer, metaLead Therapeutic

Purification Of Oligonucleotides & Their Conjugates For Progressing Early Drug Discovery Projects & The Chromatographic Challenges With Oligonucleotide G-rich Sequences
YIPING WU, Senior Scientist, AstraZeneca

Removing Biological Roadblocks To Better Treatments: The Power Of Nanofitin-Enhanced Biologics
MATHIEU CINIER, Scientific Director, Affilogi

Welcome to Cell 2025, Oxford Global’s flagship event, serving as the ultimate meeting place for bioprocessing and advanced therapy professionals. This event brings together leaders from pharma, biotech, academia, and regulatory institutions across the entire cell culture and cell & gene therapy value chain. In line with current industry trends, the event explores the transformative power of AI and machine learning in manufacturing, driving innovation and efficiency in advanced therapies.

Don't miss the opportunity to connect with over 1,000 leaders through 200+ hours of pre-arranged 1-2-1 meetings and 13+ hours of dedicated networking solutions designed to foster collaboration and accelerate advancements.

We asked key opinion leaders which breakthroughs will shape the future of advanced therapies. Automation is transforming manufacturing and analytics, making processes more efficient and scalable. At the same time, evolving regulations are working to keep pace, ensuring faster access for patients. AI/ML are driving smarter bioprocessing, while plug-and-play platforms are streamlining therapy development. In parallel, stem cell research is unlocking new possibilities in cancer treatment, and microRNA technologies are paving the way for precise gene regulation. With collaboration, innovation, and cutting-edge science, the field is advancing faster than ever. Now is the time to shape its future.

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow, Lundbeck; Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Presentation: What Does The Future Hold For Orally Available Peptides?

Presented by: Immanuel Lerner, Chief Executive Officer,
Pepticom

Oligonucleotides
Panel Discussion: The Next Chapter Of Oligonucleotide Delivery

Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK
Panellists include

Saul Martinez Montero, Senior Director, RNA Therapeutics, Dyne Therapeutics
Morten Lindow, RNAHub Founder & Mission Lead, Roche
Sritama Bose, Head Of Chemistry Research & Innovation, NATA
Fazel Shabanpoor, Co-Founder & Chief Scientific Officer & Associate Professor & Head Of Pep & Oligo Therapeutics Lab, Centron Bio & The Florey Institute

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How Vaccines & Immunotherapy Strategies: Converging Pathways For Preventing Or Treating Chronic Diseases

Presented by: Daniel Larocque, Innovation Lead, Innovation & Emerging Science, Sanofi

Daria Marsh

Head of Bioprocessing,

Catapult

Debesh Mandal

Co-Founder & Chief Executive Officer,

nanograb

Elizabeth Ramsburg

Vice President & Head of Neuroscience Research,

Spark Therapeutics

François Gianelli

Head of Regulatory and Quality,

TreeFrog Therapeutics

Joanna Brewer

Chief Scientific Officer,

Adaptimmune

Kerry Sieger

Vice President of Global Quality Operations,

Immatics US, Inc.

Lydia Caro

Associate Director, Head Of Cell Sciences,

Ichnos Sciences SA

Maria Luisa Giorello

Global Gene Therapy Platform Enablement Lead,

Pfizer Inc.

Peter Andersen

Chief Research & Development Ofﬁcer,

TreeFrog Therapeutics

Terri Gaskell

Chief Technology Officer,

Rinri Therapeutics

Thorsten Gorba

VP Manufacturing,

Aspen Neuro

Yaser Alkhatib

Head of Laboratory,

Boehringer Ingelheim RCV GmbH & Co KG

Aline Miller

Professor,

University of Manchester

Antje Presch

Team Assistant,

bih-charite.de

Bart Royens

Senior Process Engineer Manufacturing Sciences,

Sanofi

Ben Weil

Head of GMP PD Engineering,

Royal Free London NHS Foundation Trust

Bo Wiinberg

Chief Business Development Officer,

Novo Nordisk Foundation Cellerator

Bobby Gaspar

Chief Executive Officer,

Orchard Therapeutics

Chiara Recchi

Director, Research and Discovery in Gene Therapy,

Orchard Therapeutics

Christopher Middendorf

Senior Director,

Hogan Lovells

Claire Kerridge

Head of Gene Therapy,

Medicine and Healthcare Products Regulatory Agency

Claire Irvine

European and UK Patent Attorney Of Counsel,

Beck Greener

Clare Selden

Senior Lecturer,

UCL Great Ormond Street Institute of Child Health

Cornel Chiriac

Investment Director,

2050 Capital

Cristina Peixoto

Head of Downstream Process Development, Animal cell,

iBET

David Roig-Carles

Senior Scientist Process Development,

Adaptimmune

Duygu Dikicioglu

Associate Professor in Digital Bioprocess Engineering,

University College London

Edwige Gros

Senior Principal Scientist,

Amgen

Elena Piletska

Associate Professor,

Leicester Precision Medicine Institute

Eva Kokalaki

Director,

Autolus Ltd

Felix Roth

Senior Scientist,

AstraZeneca

Frank Staal

Professor of Stem Cell Biology,

Leiden University Medical Center

Giacomo Domenici

Associate Scientist,

Instituto de Biologia Experimental e Tecnológica

Hassan Mahmudul

Investment Manager,

Future Planet Capital

Henning Stennicke

Chief Scientific Officer,

Spur Therapeutics

Himansu Patel

Head of Quality,

Cell & Gene Therapy Catapult

Huaiyu Yang

Senior Lecturer,

Loughborough University

Ibon Garitaonandia

Chief Scientific Officer,

Cellprothera

Ivone Bruno

VP Preclinical Affairs and Process Development,

CytoImmune Therapeutics

James Matthews

Research Scientist,

Purespring Therapeutics

jas Uppal

Senior Vice President Regulatory Affairs,

BlueRock Therapeutics

Jon Beaman

Deputy Director Innovative Medicines ,

Pfizer Ltd

Jose Bonafont Arago

Principal Scientist,

danausgt.com

Josh Bagley

Chief Scientific Officer,

a:head bio

Julian Beach

Executive Director, Healthcare Quality and Access,

MHRA

Julie Beaudet

Chemistry, Manufacturing and Control Senior Staff Scientist,

Regeneron Pharmaceuticals, Inc.

Katerina Rigaki

Upstream Manager PD Vector,

Autolus Ltd

Katy Trost

Chief Executive Officer & Advisor,

PeraCEOs

Kenny Dalgarno

Professor,

Newcastle University

Kiran Moyo

National Senior Manager for Innovative Treatments,

Incisive Health

Kristian Tryggvason

Co-Founder, Chief Executive Officer,

Alder Therapeutics

Marcia Mata

Lead Scientist,

Cell and Gene Therapy Catapult

Marcin Jurga

Chief Scientific Officer,

EXO Biologics

Maryna Panamarova

3D Cellular Modelling Specialist, Cellular Operations,

Wellcome Sanger Institute

Matt Stone

Director of Supply Chain,

Regenxbio

Monique Schloetter

Scientific Expert Cell Therapies - Upstream Development,

Bayer

Nicole Lund

Senior QC Director,

BlueRock Therapeutics

Nirai Govindasamy

Senior Scientist,

Bluu Seafood

Nitin Patel

Vice President of Late-Stage Clinical Development,

Legend Biotech

Nozhat Choudry

Vice President of Clinical Development,

Nanoscope Therapeutics

Panteli Theocharous

Chief Therapeutics Officer and Head of Medical and Scientific Affairs,

Garuda Therapeutics, Inc.

Parag Kumthekar

Gene Therapy Downstream Process Development Lead,

UCB

Rachana Mishra

Co-Founder & Director of Cell Biology,

Secretome Therapeutics

Rhiannon David

Director Microphysiological Systems (MPS),

Astrazeneca

Robert Zweigerdt

Principal Investigator,

Hannover Medical School

Roelof Rongen

Chief Executive Officer, Board Director,

Adolore Biotherapeutics

Rohan Sivapalan

Associate Director, Cell Line Engineering & Biologics Drug Discovery,

AstraZeneca

Ruth Faram

Co-Founder & Chief Scientific Officer,

Uncommon Bio

Sabina Lancaster

Technical Programme Head,

Legend Biotech

Sally Gu

Senior Associate,

Hogan Lovells

Sanjeev Luther

President & CEO,

Eterna Therapeutics

Sarah McAleer

Pharmacy Lead Innovative Treatments,

NHS England

Sarah Snykers

Senior Director of Operations,

Legend Biotech

Seth Levy

Senior Director, Bioprocess Development,

modalis tx

Sudhish Sharma

Co-Founder & Director of Preclinical Studies,

Secretome Therapeutics

Sven Kili

Partner,

Saisei Ventures

Taisiia Mukii

Founding Ambassador,

Women in STEM Network

Tamara Straub

Scientific Leader,

Boehringer Ingelheim RCV GmbH & Co KG

Tatyana Ponomaryov

Principal Scientist,

Plasticell Limited

Thijs Gerritzen

Director CMC development,

Amarna Therapeutics B.V.

Tiffany Rao

Professor Biochemistry and Cell Biology,

University College Cork

Ulrich Rümenapp

Senior Biotech Program Lead,

Bayer AG

Vasiliki Kalodimou

Assist. Professor Dr/Director Flow Cytometry-Research & Regenerative Medicine,

EUC Frankfurt Branch

Vincenzo Di Cerbo

Lead Scientist,

Cell and Gene Therapy Catapult

Volker Huppert

Chief Operating Officer,

Glycostem Therapeutics B.V.

GenScript

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

Advanced Therapies Specialist Team Leader,
Genscript

Biosystems Acro

Biologics 2024 has been one of the best events I have attended so far in my career.

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Bioassay

Impressed by the effort to bring people together.

Business Development Director,

Bioassay

IpA

Nice set-up, with good support for exhibitors

Director of Client Relations,

ImmunoPrecise

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

In-Person Services Digital Marketing Services

Interested in Sponsoring Cell 2025?

Become a driving force in connecting leaders from every stage of the value chain to drive advanced therapy development & novel biologics processing. Cell 2025 offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Find Out More